Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Cash from Financing Activities (2023 - 2025)

Historic Cash from Financing Activities for Contineum Therapeutics (CTNM) over the last 3 years, with Q3 2025 value amounting to $19.1 million.

  • Contineum Therapeutics' Cash from Financing Activities rose 14686153.85% to $19.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.9 million, marking a year-over-year decrease of 8161.57%. This contributed to the annual value of $109.0 million for FY2024, which is 9403.48% up from last year.
  • Per Contineum Therapeutics' latest filing, its Cash from Financing Activities stood at $19.1 million for Q3 2025, which was up 14686153.85% from $91000.0 recorded in Q2 2025.
  • Over the past 5 years, Contineum Therapeutics' Cash from Financing Activities peaked at $108.4 million during Q2 2024, and registered a low of -$617000.0 during Q1 2023.
  • Its 3-year average for Cash from Financing Activities is $16.8 million, with a median of $91000.0 in 2025.
  • Examining YoY changes over the last 5 years, Contineum Therapeutics' Cash from Financing Activities showed a top increase of 14686153.85% in 2025 and a maximum decrease of 9991.6% in 2025.
  • Contineum Therapeutics' Cash from Financing Activities (Quarter) stood at -$321000.0 in 2023, then skyrocketed by 300.0% to $642000.0 in 2024, then surged by 2875.86% to $19.1 million in 2025.
  • Its last three reported values are $19.1 million in Q3 2025, $91000.0 for Q2 2025, and $24000.0 during Q1 2025.